DVAX - Dynavax Technologies Corporation

Dynavax Technologies Corp, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said. {nL2N1M72GW] - https://finance.yahoo.com/news/deals-day-mergers-acquisitions-134544367.html

 

Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults - https://finance.yahoo.com/news/dynavax-announces-fda-approval-heplisav-214519448.html

 

If this goes down to $17.10 that would be a great buying opportunity, with the Hep B vaccination approved.

 

Just took a couple days to get down to below $18. Bottom of Bollinger band right now.

 

Current ~10.25, still got an eye on this. Had ER this evening.

 

Whew, maybe it finally can't go any lower.

 

DVAX is finally cash flow-positive.
The revenue forecasts are all over the place (Q2 is currently forecast only half of Q1, 2023 revenues are currently forecast lower than this year), so we'll see if they can firm that up.

 

Revenue forecasts are still all over the place; they need to get analysts on board that they will keep growing.
Next ER 11/4.
Making higher lows as it bumps against $20 resistance.

 

Great chart!